The Future of Psychedelic Regulation Is Local

Psychedelic regulation should be led by state agencies rather than waiting for federal FDA approval. The argument points to an August 2024 FDA rejection of an initial application for federally approved psychedelic-assisted therapy, and says this setback clarifies the state driven path instead of halting progress. Because federal agencies oversee drugs but not medical practice, a successful FDA approval would have raised difficult questions about who provides care, insurance coverage, and how therapies would be governed. The piece highlights Oregon’s 2020 Psilocybin Services Act and Colorado’s 2022 Natural Medicine Health Act as early frameworks that combine regulated access with decriminalization and protections for personal and religious liberty. It also proposes an incremental policy approach: states could authorize psychedelic cultivation and distribution through existing cannabis infrastructure, using dispensaries to reduce startup costs and leverage established compliance systems.